Dissecting the Genetic Environment Contributions of Autoimmune Liver Disease

Overview

About this study

The overall objective of this proposal is to conduct a systematic approach to dissect both genetic underpinnings and non-genetic factors in the development of adult autoimmune liver diseases including autoimmune hepatitis (AIH), overlap AIH with Primary Biliary Cirrhosis (AIH-PBC), overlap AIH with Primary Sclerosing Cholangitis (AIH-PSC), and drug-induced autoimmune-like hepatitis (DIAIH).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

AIH patients

  • Male and female patients ages ≥ 7 years old.
  • Diagnosis of probable AIH on the pretreatment score as defined by the International Autoimmune Hepatitis Group (IAIHG) revised criteria or
  • Diagnosis of probable AIH confirmed by the IAIHG Simplified Criteria for the Diagnosis of Autoimmune Hepatitis score

AIH-PBC Patients

  • Male and Female patients ages ≥ 7 years old.
  • Diagnosis of AIH-PBC overlap syndrome defined by the association of PBC and probable AIH either simultaneously or consecutively. 

AIH-PSC Patients

  • Male and Female patients ages ≥ 7 years old.

Diagnosis of AIH-PSC overlap syndrome defined by association of PSC and probable AIH

DIAIH Patients

  • Male and Female patients ages ≥ 7 years old.
  • Diagnosis of probable AIH on the pretreatment score as defined by the International Autoimmune Hepatitis Group (IAIHG) revised criteria or
  • Diagnosis of probable AIH confirmed by the IAIHG Simplified Criteria for the Diagnosis of Autoimmune Hepatitis score
  • Presence of a suspicion of drug etiology in triggering an AIH clinical picture.

Control Patients

  • Male and Female patients ages ≥ 7 years old.
  • No evidence, history or diagnosis of a chronic liver disease in medical history

Exclusion Criteria:

All AIH, overlap, DIAIH patients, and controls:

  • Prisoners and institutionalized individuals
  • Patients unable to provide consent

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Konstantinos Lazaridis, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20314738

Mayo Clinic Footer